title: [Clinical effectiveness of dehelmintization in patients with psoriasis accompanied by chronic opisthorchosis].
abstract: The purpose of the study was to prove the appropriateness of dehelmintization in patients with psoriasis accompanied by chronic opisthorchosis (CO). The authors examined 150 patients with psoriasis accompanied by CO, 100 patients having psoriasis without helminthiasis, 100 patients with psoriasis and 30 healthy individuals. Gastric secretion was evaluated by means of the fractional test (both phases) with histamine stimulation; other diagnostic procedures included carbohydrate absorption evaluation (5-gram D-Xylose absorption test), Kamer test of fat absorption and evaluation of small intestine bioelectric activity by means of electromyography. The patients were followed up within 2 to 3 years. The study found negative dynamics in the parameters of gastric secretion, fat and D-xylose absorption and small intestine bioelectric activity in patients with psoriasis and CO within the 2-3-year follow-up, while the group of dehelmintized patients displayed significant improvement of these parameters. Thus, effective dehelmintization allowed improvement of alimentary tract functional condition and the clinical course of psoriasis.
authors.forename: S A
authors.initials: SA
authors.lastname: Khardikova
authors.forename: E I
authors.initials: EI
authors.lastname: Beloborodova
authors.forename: P N
authors.initials: PN
authors.lastname: Pesterev
mesh_terms: D000328:Adult; D000818:Animals; D000909:Antibodies, Helminth / Q000276:immunology; D000969:Antinematodal Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004576:Electromyography; D005223:Fats / Q000493:pharmacokinetics; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007421:Intestine, Small / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D009889:Opisthorchiasis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D009891:Opisthorchis / Q000276:immunology; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D013270:Stomach / Q000503:physiopathology; D016896:Treatment Outcome; D014994:Xylose / Q000493:pharmacokinetics / Q000652:urine
chemical_list: D000909:Antibodies, Helminth; D000969:Antinematodal Agents; D005223:Fats; D014994:Xylose